Page 187 - Eceptor News Today

Researchers investigated the immunogenicity of a novel adjuvant comprised of a modified porous silicon microparticle for the SARS-CoV-2 S protein RBD subunit vaccine.

Researchers used viral pseudotyping to examine whether variants of concern had different host ACE2 receptor usage patterns.

A new study suggests that infection-induced antibodies persist, providing protection for at least six months.

Researchers compared the distribution of SARS-CoV-2 genotypes to the prevalence of SARS-CoV-2 variants.

Researchers from the Instituto Venezolano de Investigaciones Científica investigate the introduction of one of the VOCs into Venezuela.

New research from The University of Texas MD Anderson Cancer Center found that treatment with antihistamines, a commonly used allergy medication, was associated with improved responses to immune checkpoint inhibitors.

A study developed a protein-based subunit vaccine, PHH-1V, that consisted of a recombinant RBD fusion heterodimer of the alpha) and beta variants of SARS-CoV-2.

A multi-institutional team of investigators led by bioengineer Ankur Singh has developed research tools that shed new light on a virtually untreatable form of prostate cancer, opening a pathway that may lead to novel therapeutics and a glimmer of hope for patients.

When something disrupts hormone binding to the receptor, such as environmental compounds or pollutants, called endocrine disrupting chemicals (EDCs), the results can be harmful and, in some cases, lead to certain forms of cancer.

​On November 23, 2021, the California Institute for Regenerative Medicine (CIRM) governing board approved a $4.1 million grant to enable University of California San Diego School of Medicine researchers to advance a new chimeric antigen receptor (CAR) T-cell therapy from the laboratory into the clinic.